ClinicalTrials.gg
RecruitingNCT06875583REDUCEUpdated Nov 24, 2025

The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial

An interventional study of Radiation in Radiation Exposure, Radiation Exposure to Operator and Radiation Injuries, sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 16 studies in Radiation Injuries with a site in United Kingdom — 3 open to participants now, 4 under way, none of them phase 3. Radiation Injuries · United Kingdom.

Started
2025
the only one that year
No phase
5 of 16
1 open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
Liverpool Heart and Chest Hospital NHS Foundation Trust

Among the 16 studies in Radiation Injuries with a site in United Kingdom, this one is the only one that started in 2025, is one of 5 with no phase, and was the 15th registered.

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

Browse Radiation Injuries studies →

Open to participants now

3 of the 16 studies in Radiation Injuries with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 76 Radiation Injuries studies recruiting now, 52 (68%) set no upper age limit and 14 (18%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Radiation Injuries with a site in United Kingdom, or all of them as a file.
02

Study summary

Doctors and nurses who perform heart procedures using X-ray guidance are exposed to radiation, which can be harmful over time. This exposure increases the risk of certain health problems, including cancers, eye damage (cataracts), and DNA damage. Although protective lead clothing is used to reduce exposure, it is heavy, uncomfortable, and can cause muscle and joint problems for those who wear it daily.

A new radiation protection device, called RAMPART, may help reduce radiation exposure for heart specialists and their teams. It could also allow them to wear lighter protective gear-or none at all-making their work safer and more comfortable.

This study will compare the radiation levels received by doctors and nurses during heart procedures when using RAMPART versus standard protection. By doing so, we hope to find out if this new device can better protect medical teams from radiation, improving both their safety and well-being.

Read the detailed description

Recent decades have seen major increases in x-ray guided procedures in interventional cardiology, radiology and vascular surgery. Exposure to ionising radiation is known to be an inherent risk and remains a serious and unresolved threat to the health of operators and their team. It is associated with an increased incidence of brain and blood cancers, cataracts, and recent mechanistic data indicates significantly increased DNA damage in those without leaded leg protection.

Although existing standard radiation protection measures somewhat reduces exposure, all cardiac catheter lab personnel still receive a certain dose of radiation and continue to accumulate lifetime exposure. Furthermore, leaded personal protective equipment is heavy, leads to orthopaedic complications, and detracts from operator comfort.

Novel radiation protection devices such as RAMPART may significantly reduce radiation doses to cardiac catheter lab personnel, and potentially allow the use of lighter lead, or no lead at all. In this study we aim to investigate if use of RAMPART significantly reduces radiation exposure, when compared with standard radiation protection. Standard coronary intervention procedures will be randomised to RAMPART or standard (radiation protection), and operators and Cath lab team doses will be compared.

03

Conditions studied

  • Radiation Exposure
  • Radiation Exposure to Operator
  • Radiation Injuries
  • Radiation Safety

Browse trials for

Keywords

  • radiation exposure
  • radiation exposure to operator
  • radiation injuries
  • radiation safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All procedures involving adult patients (>18 year of age)
  • Male or female patients
  • Planned to undergo either an elective or urgent coronary intervention procedure involving ionising radiation in the cardiac catheter lab, via the right and or left radial arteries.

Exclusion criteria

Exclusion Criteria:

  • Procedures involving patients less than 18 years of age
  • Patients unable to give valid consent
  • Pregnancy
  • Femoral approach procedure
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    RAMPART Arm

    The use of the RAMPART system to reduce operator radiation exposure

    Device: Radiation

  • No intervention
    Standard Arm

    Standard radiation protection

Interventions

  • DeviceRadiation

    The use of RAMPART radiation protection device

    Also known as: Use of RAMPART radiation protection device

06

What researchers measure

Primary outcomes

  1. 1st Operator Eye radiation

    To assess the effect of using a new medical device (RAMPART) in reducing the amount of radiation the first operator is exposed to (at eye level) when performing coronary angiography or angioplasty. Measurement of radiation in µSv.

    Time frame: 1) Periprocedural 2) Cumulative dose - through study completion, an average of 1 year

Secondary outcomes

  1. 1st Operator Chest / Groind radiation

    To assess if RAMPART significantly reduces the radiation dose to first operators during coronary angiography or angioplasty at chest and groin level. Measurement of radiation in µSv.

    Time frame: 1) Periprocedural 2) Cumulative dose - through study completion, an average of 1 year

  2. 2nd Operator Radiation - all levels

    To assess if RAMPART significantly reduces the radiation dose to second operators during coronary angiography or angioplasty at the level of eye, chest and groin. Measurement of radiation in µSv.

    Time frame: 1) Periprocedural 2) Cumulative dose - through study completion, an average of 1 year

  3. 'Circulating Nurse' Radiation

    To assess if RAMPART significantly reduces radiation dose in a more distant position, consistent with that of a 'circulating nurse'. Measurement of radiation in µSv.

    Time frame: 1) Periprocedural 2) Cumulative dose - through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lisko JC, Shekiladze N, Chamoun J, Sheikh N, Rainer K, Wei J, Binongo J, Raj L, Byku I, Rinfret S, Devireddy C, Jaber WA, Greenbaum AB, Babaliaros V, Steuterman S, Sandesara P, Nicholson WJ. Radiation Exposure Using Rampart vs Standard Lead Aprons and Shields During Invasive Cardiovascular Procedures. J Soc Cardiovasc Angiogr Interv. 2023 Oct 19;3(1):101184. doi: 10.1016/j.jscai.2023.101184. eCollection 2024 Jan. PubMed 39131978 ↗
  • Noor HA, Althawadi N, Noor Z, AlAnsari N, Chachar TS, Al Raisi S, Yousif N. Radiation Exposure During Invasive Cardiovascular Procedures: Portable Shielding System Versus Standard Lead Aprons. Cureus. 2024 Aug 29;16(8):e68108. doi: 10.7759/cureus.68108. eCollection 2024 Aug. PubMed 39350833 ↗

Individual participant data

Plan to share: Yes — Direct access will be granted to the Sponsor, host institution and the regulatory authorities to permit trial-related monitoring, audits and inspections in line with participant consent. Furthermore, all data will be shared through publication and via online additional data supplements.

Supporting information: Study protocol, Clinical study report

Time frame: End of trial and publication

Access criteria: Published Journal platform Open Source Framework - https://osf.io/

Data sharing details ↗ · osf.io

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2026, 6 months after the start.

Of 69 non-industry interventional studies with no phase under Radiation Injuries, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 6 months is below that.

Counting every sponsor, half of 72 studies reached it within 43 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Mar 13, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06875583
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborators
Rampart Health, L.L.C.
Responsible party
John Hung (Consultant Cardiologist, Chief Investigator, Liverpool Heart and Chest Hospital NHS Foundation Trust) — Principal investigator
First posted
Mar 13, 2025
Start date
Aug 29, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

John D Hung, MBChB PhD MRCP(UK)
Contact
paula.walker@lhch.nhs.uk
0151 600 1657 ext. 0151 600 1657
Debar Rasoul, MBChB BSc MRCP(UK)
Contact
paula.walker@lhch.nhs.uk
0151 600 1657 ext. 0151 600 1657

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion